Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113117
Chunk: 96

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 96
---
 off of deferred offering costs during the three months ended September 30, 2025 as compared to $0
during the three months ended September 30, 2024.

Net loss and net loss attributable to common stockholders

For the three months ended September 30, 2025 and 2024, net loss amounted
to $4,856,000 and $4,228,000, respectively, which represents an increase in net loss of $628,000, or 14.9%. During the three months ended
September 30, 2025, in connection with our Series D Preferred Stock down round triggering event, we recorded deemed dividends of $6,650,000.
Accordingly, for the three months ended September 30, 2025 and 2024, net loss attributable to common stockholders amounted to $11,506,000,
or $(9.10) per common share, and $4,228,000, or $(170.22) per common share, respectively.

<div align='center'>39</div>

Results of Operations for the Nine Months Ended September 30, 2025 and 2024

The results of operations
for the nine months ended September 30, 2024 are pro forma as the period presented in the following table and discussion includes
the Predecessor for the period from January 1, 2024 through February 13, 2024 and the Company for the period from February 14, 2024 through
September 30, 2024. This pro forma period from January 1, 2024 to September 30, 2024 does not include the Merger transactions that occurred
on-the-line.

| Operating expenses:                                        |     | For the Nine Months Ended 
 September 30,             
 2025                      
 (Successor)               |             |   |     | 2024           
 (Pro forma)    
 (Predecessor   
 and Successor) |             |   |     | Difference |             |   |     | Percentage 
 Change     |        |    |
|:-----------------------------------------------------------|:----|:--------------------------|------------:|:--|:----|:---------------|------------:|:--|:----|:-----------|------------:|:--|:----|:-----------|-------:|:---|
| Research and development                                   |     | $                         |   8,048,034 |   |     | $              |   6,